Endocyte stock sinks due to possible drug-filing delay

Back to TopCommentsE-mailPrintBookmark and Share

Endocyte Inc. saw its shares fall nearly 7 percent Tuesday morning after the drug development firm announced that its application for U.S. approval of a cancer treatment could be delayed another 10 months.

West Lafayette-based Endocyte is developing an ovarian cancer drug called vintafolide, which would be the first new drug approved to treat the painful cancer in more than a decade.

Its shares fell to as low as $8.50 each in morning trading after the company released fourth-quarter financial results Monday following the close of financial markets.

Endocyte has applied for approval of vintafolide in Europe, at the encouragement of regulators there, even before it completed a Phase 3 clinical trial.

But, in the United States, Endocyte will need to complete its Phase 3 trial before the Food and Drug Administration will consider it for market approval.

That Phase 3 trial was supposed to end in the first half of 2014 but now may last another nine to 10 months.

That’s because Endocyte and its development partner, New Jersey-based Merck & Co. Inc., have lined up a plan to test 100 extra patients next year in order to have better data on vintafolide’s ability to prolong patients’ lives.

As it stands, Endocyte’s Phase 3 trial of vintafolide will include just 250 patients and is designed to measure only the amount of time the drug extends the time in which patients have no regression of ovarian cancer.

But the FDA has been increasingly interested in seeing cancer drugs not only improve patients’ progression-free survival timelines, but also to lengthen their lives, which is called overall survival, or OS.

“I think it’s safe to say that we have a much, a better chance, of course, of hitting an OS endpoint at 350 [patients] than we do at 250,” Endocyte CEO Ron Ellis told Wall Street analysts during a conference call Monday evening.

The downside of that decision is that it delays the timeline for potential approval of vintafolide in the United States.

Endocyte has no products on the market, and is slowly burning through cash it raised via two public offerings in 2011.

The company had more than $200 million in cash on hand at the end of 2012, but expects to spend $65 million in 2013.

Much of Endocyte’s research on vintafolide is supported by Merck, which now includes studies in lung and breast cancer. For example, Merck will pay 75 percent of the costs of enrolling the extra 100 patients in Endocyte's ovarian cancer study. Merck has also committed to help Endocyte commercialize the drug in Europe.

The companies expect to receive a decision from European regulators on whether vintafolide can be sold there by the end of 2013.

In the fourth quarter of 2012, Endocyte lost $849,000, or 2 cents per share, on revenue of $14.5 million, most of which came from Merck.

For all of 2012, Endocyte lost $17.3 million, or 48 cents per share, an improvement from the previous year’s loss of $40.5 million, or $1.40 per share.

Its full-year revenue totaled $34.7 million, compared with $191,000 in the previous year.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
thisissue1-092914.jpg 092914

Subscribe to IBJ
  1. Here are a few candidates for this new group, "ripped from the headlines." First up, that bizzaro State Senator Brent Waltz; secondly, the unethical Todd Huston, and his contractual arrangements scheme; Finally, but not least of all, the dishonorable Eric Turner. What sayeth you Greg Zoeller?

  2. Good day. I can't hide this great testimony that take place in my life I will love everyone to know it and be partaker that is why I always place it on answer, I am Mrs,Natalie Cuttaia by name, I live in Texas, United State Of America, I want to thank (Mr.Bruce Brandon) for his kindness upon my family life. I never knew that there is still nice lender like this on internet and earth here. Just some Months Back, I was in search for a loan of $100,000,00 as I was running out of money for feeding and rent. I was scammed $6,800 Dollars and I decided not to involve my self in such business again but a Friend of my introduced me to a loan firm due to my appearance and doings. And I told him that I am not interested of any loan deal anymore but he told me that there is still a nice lender who he will recommend me to, and I made a trial and I am most grateful lucky am I today, I was given a loan amount of $100,000.00usd, by this great Company (Bruce Brandon Loan Company) managed by (Mr.Bruce Brandon) If you are in need of a genuine or legit loan or financial assistance and you can be reliable and trusted of capable of paying back at the due time of the funds I will advice you to, contact him via: ( bruce.brandon071@gmail.com ) And you will be free from scams in the internet. All thanks to Mr.Bruce Brandon You are the one who remove me and my family out of poverty. The reason why i am doing this is that, i promise Mr.Bruce Brandon that if i truly got my loan, i will advertize his company and bring customers to his company. Contact him via ( bruce.brandon071@gmail.com )for the Loan you have been looking for..

  3. Hello, We are firm Organization formed to help people in needs of helps,such as financial help. So if you are going through financial difficulty or you are in any financial mess,and you need funds to start up your own business,or you need loan to settle your debt or pay off your bills,start a nice business, or you are finding it hard to obtain capital loan from local banks,contact us today via email mrsroseberrywilkinsfunds.usa@gmail.com So do not let these opportunity pass you by because Jesus is the same yesterday, today and forever more. Please these is for serious minded and God fearing People. Your Name: Loan Amount: Loan Duration: Valid Cell Phone Number: Thanks for your understanding to your contact as we Await Regards Management Email:mrsroseberrywilkinsfunds.usa@gmail.com

  4. The question is, where could they build a new stadium? It seems in the past year, all the prime spots have been spoken for with potential projects. Maybe in the industrial wasteland area a block past Lucas Oil? I think it needs to be close to the core, if a new stadium is built.

  5. Aldi is generally a great shopping experience. Still, I'm sure YOU wouldn't want to shop there, which I consider a positive.